Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity
Conclusions: Patients with spasticity can expect a characteristic profile of BoNT-A effects, namely time lag to onset and peak effect followed by a gradual decline in the symptomatic benefits. Symptom re-emergence is common and has significant impact on quality of life. Greater patient/clinician awareness of this therapeutic profile should lead to better level of overall satisfaction with treatment, informed therapeutic discussions and treatment schedule planning.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Back Pain | Brain | Depression | France Health | Germany Health | Internet | Italy Health | Neurology | Pain | Pain Management | Sleep Disorders | Sleep Medicine | Spinal Cord Injury | Stroke